Inclusion Criteria:  ECOG Performance Status equal to or less than 2 within 30 days prior to registration Revised International Staging System (R-ISS) I,2 or 3 Patients with multiple myeloma as defined by IMWG Received at least 3 years of post ASCT maintenance (patients may have received any number of prior lines of therapy). Maintenance therapy is defined as any anti-myeloma therapy initiated after ASCT to prevent disease recurrence and prolong time in remission (i.e., lenalidomide, bortezomib, RVD, etc.) Disease response is VGPR or CR at the time of enrollment as defined by IMWG criteria. Patients must be able to understand and be willing to sign a voluntary informed consent form and agree to compliance with the protocol schedule; with the knowledge that they may withdraw consent at any time without impact on future medical care  Exclusion Criteria:  Patients with plasma cell leukemia, AL amyloidosis or Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin (POEMS) syndrome Prior organ transplant or condition requiring immunosuppressive therapy Prior allogeneic hematopoietic cell transplant Treatment with any investigational drug within 30 days prior to enrollment Unable to sign an informed consent